MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance

Immunology and Microbiology

• Regulatory T Cell 100%
• Electric Potential 20%
• CD4 20%
• Tumor-Associated Macrophage 20%
• Conjugation 20%
• Immunotherapy 20%
• Syngenic 20%
• Antineoplastic Activity 20%
• Cell Growth 20%
• Immunomodulating Drugs 20%
• STAT5 20%
• Immune Cell Homeostasis 20%
• Active Immunotherapy 20%
• Cells 20%
• Life 20%
• Cytotoxic T-Cell 20%

Neuroscience

• Adverse Effect 60%
• In Vivo 40%
• Cell Growth 20%
• In Vitro 20%
• CD4 20%
• Albumin 20%
• Serum Albumin 20%
• STAT5 20%
• Immunotherapy 20%